Positive topline results from a planned interim analysis of the DESTINY-Breast05 phase 3 trial showed ENHERTU demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) versus trastuzumab emtansine in patients with HER2 positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence. This is the second positive phase 3 trial of ENHERTU in the HER2 positive early breast cancer setting following positive results from the DESTINY-Breast11 phase 3 neoadjuvant trial earlier this year. Overall survival was not mature at the time of this planned interim analysis and will be assessed at a subsequent analysis. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo (DSNKY) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca Stock (AZN) Looking Perkier on U.S. and U.K. Dual Listing Plan
- Trump Weekly: President threatens new tariffs, announces TikTok deal
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- AstraZeneca launches AstraZeneca Direct
- Tempus AI price target raised to $95 from $80 at Guggenheim